One Day It Will Be Too Late
$RGBP - Regen Biopharma, Inc.
People are Sleeping on This One. Good Positive Volume Moves it Up.
Needs a Better Following-More Volume-Quality BioTech Stem Cell.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Main Focus is the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.They are utilizing Patients Own Immune Systems in Trials.
Eli Lilly (LLY) & RGBP Partner in Small Molecules Immuno-Oncology - Autoimmunization NR2F6 Program. They Currently Await New Patents, Etc. News of Approval.
The Intended Result is Oral Drugs-Therapies-Treatment for Cancers & Auto Immune Diseases.
Specializing in Cutting Edge Technology.
Areas of interest to the Company include:
- Hematopoiesis (Blood formation)
- Breast Cancer
- Liver Cancer
- Leukemia
- Myelodysplastic Syndrome
- Aplastic Anemia
- Auto Immune Diseases/Disorders
Small Molecules Targeting Cancer and Autoimmunity
Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
- Objective is to identify small molecules that can activate and inhibit NR2F6
- Currently in pre-clinical development
- Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
- Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
- Additional indications include solid tumors, acute leukemia and GVHD
HemaXellerate
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
- Fat stem cell based product to treat bone marrow that has been damaged
- Bone marrow damage occurs from radiation, chemo, or chronic conditions
- HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
- United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
dCellVax
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
- 10 advanced breast cancer patients
- Efficacy endpoints at 6 and 12 months
- Establishment of safety will allow for rapid expansion of patient numbers
- Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program
DiffronC
Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
- siRNA silencing of our newly discovered cancer stem cell target gene
- Silencing using DiffronC induces differentiation of cancer cells
- Initial indication is treatment of myelodysplastic syndrome
- Other indications include solid tumors and acute leukemia
Telomeres & Genomic Integrity
Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
- Telomeres are protective structures at the ends of chromosomes that enable cell divisions
- Telomere attrition is involved in aging, cancer and genetic mutations
- We are developing drugs that modulate telomere maintenance
- In pre-clinical development for indications of solid cancers and acute leukemia
https://www.regenbiopharmainc.com
https://finance.yahoo.com/quote/RGBP?p=RGBP&.tsrc=fin-srch
https://www.otcmarkets.com/stock/RGBP/overview
One Day They'll Wake Up To News of a Buyout-Merge. The Potential is Real.
Similar Company's a Little Ahead of Regen were Bought Out for Billions.
LONG PLAY - SHORT TERM GAIN POTENTIAL - Up To 400% In Past - Recently 17.32%
If You have a Need For More Information-Contact Me
You Can Also Go To Our Web Site and Request to be Added to Our Subscriber List for Emails. You'll only get the Latest News/PR/Filings and an occasional update.
Robert E. Kreh – Principal
Small Cap Solutions, LLC
robkreh@smallcapsolutions.com
(443) 567-2609
https://www.smallcapsolutions.com
( OTCQB:RGBP ) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker( S )/Broker Dealer with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
